Board Walk - October 2021.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Works matching IS 03331024 AND DT 2021 AND VI 41 AND IP 11/12
Results: 16
1
2
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1222, doi. 10.1177/03331024211018137
- By:
- Publication type:
- Article
3
Association and genetic overlap between clinical chemistry tests and migraine.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1208, doi. 10.1177/03331024211018131
- By:
- Publication type:
- Article
4
Postprandial fasting related headache during Ramadan in Saudi Arabia: A cross-sectional study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1201, doi. 10.1177/03331024211017915
- By:
- Publication type:
- Article
5
Targeting reactive nitroxidative species in preclinical models of migraine.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1187, doi. 10.1177/03331024211017884
- By:
- Publication type:
- Article
6
Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1249, doi. 10.1177/03331024211017882
- By:
- Publication type:
- Article
7
Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1272, doi. 10.1177/03331024211017879
- By:
- Publication type:
- Article
8
CGRP release in an experimental human trigeminal pain model.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1268, doi. 10.1177/03331024211017250
- By:
- Publication type:
- Article
9
Photophobia in migraine: A symptom cluster?
- Published in:
- 2021
- By:
- Publication type:
- journal article
10
Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1276, doi. 10.1177/03331024211014625
- By:
- Publication type:
- Article
11
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1181, doi. 10.1177/03331024211014616
- By:
- Publication type:
- Article
12
Severe abrupt (thunderclap) non-traumatic headache at the pediatric emergency department – a retrospective study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1172, doi. 10.1177/03331024211014612
- By:
- Publication type:
- Article
13
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
- Published in:
- 2021
- By:
- Publication type:
- journal article
14
Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1262, doi. 10.1177/03331024211010308
- By:
- Publication type:
- Article
15
E-diary use in clinical headache practice: A prospective observational study.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1161, doi. 10.1177/03331024211010306
- By:
- Publication type:
- Article
16
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
- Published in:
- Cephalalgia, 2021, v. 41, n. 11/12, p. 1152, doi. 10.1177/03331024211010305
- By:
- Publication type:
- Article